Results from a phase 1b multiple ascending-dose study of prx002, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson's disease

被引：0
|
作者：
Jankovic, J.
Goodman, I.
Safirstein, B.
Schenk, D.
Kinney, G.
Koller, M.
Ness, D.
Griffith, S.
Grundman, M.
Soto, J.
Ostrowitzki, S.
Boess, F.
Martin-Facklam, M.
Quinn, J.
Isaacson, S.
Jennings, D.
Omidvar, O.
Ellenbogen, A.
机构：
来源：
MOVEMENT DISORDERS | 2017年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1418
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy Results from the Phase 2b SYNERGY Study: Treatment of Disabling Multiple Sclerosis with the Anti-LINGO-1 Monoclonal Antibody Opicinumab
    Mellion, Michelle
    Edwards, Keith R.
    Hupperts, Raymond
    Drulovic, Jelena
    Montalban, Xavier
    Hartung, Hans-Peter
    Brochet, Bruno
    Calabresi, Peter A.
    Rudick, Richard
    Ibrahim, Adama
    Zhang, Yiwei
    Xu, Lei
    Cadavid, Diego
    NEUROLOGY, 2017, 88
  • [22] EFAVALEUKIN ALFA, A NOVEL IL-2 MUTEIN, SELECTIVELY EXPANDS REGULATORY T CELLS IN PATIENTS WITH SLE: FINAL RESULTS OF A PHASE 1B MULTIPLE ASCENDING DOSE STUDY
    Tchao, N.
    Sarkar, N.
    Hu, X.
    Zhang, R.
    Milmont, C.
    Jin, Y. Shi
    Chow, V.
    Kroenke, M.
    Gorski, K.
    Furie, R.
    Kivitz, A.
    Cohen, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1343 - 1344
  • [23] Efavaleukin Alfa, a Novel IL-2 Mutein, Selectively Expands Regulatory T Cells in Patients with SLE: Interim Results of a Phase 1b Multiple Ascending Dose Study
    Tchao, Nadia
    Amouzadeh, Hamid
    Sarkar, Nandita
    Chow, Vincent
    Hu, Xuguang
    Kroenke, Mark
    Wang, Hui
    Zhang, Rong
    Gorski, Kevin
    Furie, Richard
    Kivitz, Alan
    Cohen, Stanley
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3613 - 3615
  • [24] Safety, tolerability, and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: A single and multiple ascending dose phase 1b/2a clinical trial
    Hernandez, Gerson D.
    Solinsky, Christine M.
    Mack, Wendy J.
    Kono, Naoko
    Rodgers, Kathleen E.
    Wu, Chun-Yi
    Mollo, Ana R.
    Lopez, Claudia M.
    Pawluczyk, Sonia
    Bauer, Gerhard
    Matthews, Dawn
    Shi, Yonggang
    Law, Meng
    Rogawski, Michael A.
    Schneider, Lon S.
    Brinton, Roberta D.
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2020, 6 (01)
  • [25] CALY-002, AN ANTI-IL-15 ANTIBODY, RESULTS IN HISTOLOGICAL AND CLINICAL IMPROVEMENT IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS IN A PHASE 1A/B STUDY
    Bredenoord, Arjan
    Houbiers, Jos G.
    Vanuytsel, Tim
    Chvatchko, Yolande
    Hoff, Dag Arne
    Conchillo, Jose M.
    Dellon, Evan S.
    Tran, Isabelle
    Guyon-Gellin, Nicolas
    Holz, Josefin-Beate
    Vicari, Alain
    GASTROENTEROLOGY, 2024, 166 (05) : S228 - S229
  • [26] Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)
    Naoya Yamazaki
    Tatsuya Takenouchi
    Manabu Fujimoto
    Hironobu Ihn
    Hiroshi Uchi
    Takashi Inozume
    Yoshio Kiyohara
    Hisashi Uhara
    Kazuhiko Nakagawa
    Hiroshi Furukawa
    Hidefumi Wada
    Kazuo Noguchi
    Takashi Shimamoto
    Kenji Yokota
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 651 - 660
  • [27] Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)
    Yamazaki, Naoya
    Takenouchi, Tatsuya
    Fujimoto, Manabu
    Ihn, Hironobu
    Uchi, Hiroshi
    Inozume, Takashi
    Kiyohara, Yoshio
    Uhara, Hisashi
    Nakagawa, Kazuhiko
    Furukawa, Hiroshi
    Wada, Hidefumi
    Noguchi, Kazuo
    Shimamoto, Takashi
    Yokota, Kenji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (04) : 651 - 660
  • [28] Preliminary results of a phase III study of HuZAF, an anti-IFN-γ monoclonal antibody, in patients with moderate to severe active Crohn's disease
    Rutgeerts, P
    Reinisch, W
    Colombel, JF
    Gendre, JP
    Van Deventer, S
    Oldenburg, B
    Modigliani, R
    Layug, B
    Cheong, M
    O'Connor, J
    Levitt, D
    GASTROENTEROLOGY, 2002, 122 (04) : A61 - A61
  • [29] FIRST RESULTS FROM A PHASE 1B STUDY OF THE ANTI-EPCAM ANTIBODY ADECATUMUMAB (MT201) IN COMBINATION WITH DOCETAXEL IN PATIENTS WITH METASTATIC BREAST CANCER
    Schuler, M.
    Hanusch, C.
    Steger, G. G.
    Schmidt, M.
    Lang, A.
    Wolf, C.
    Sebastian, M.
    Schmidt, M.
    Reinhardt, C.
    Eiermann, W.
    ANNALS OF ONCOLOGY, 2008, 19 : 160 - 161
  • [30] Randomized, Placebo-Controlled, Phase 1b study of the anti-Beta-amyloid antibody Aducanumab (BHB037) in patients with prodromal or Mild Alzheimer's Disease: interim results
    Viglietta, V.
    Williams, L.
    Chen, T.
    O'Gorman, J.
    Chiao, P.
    Hock, C.
    Nitsch, R. M.
    Sandrock, A.
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 53 : S12 - S13
12345